Unknown

Dataset Information

0

Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo.


ABSTRACT:

Background

IL-33 is one of the most consistently associated gene candidates for asthma identified by using a genome-wide association study. Studies in mice and in human cells have confirmed the importance of IL-33 in inducing type 2 cytokine production from both group 2 innate lymphoid cells (ILC2s) and TH2 cells. However, there are no pharmacologic agents known to inhibit IL-33 release from airway cells.

Objective

We sought to determine the effect of glucagon-like peptide 1 receptor (GLP-1R) signaling on aeroallergen-induced airway IL-33 production and release and on innate type 2 airway inflammation.

Methods

BALB/c mice were challenged intranasally with Alternaria extract for 4 consecutive days. GLP-1R agonist or vehicle was administered starting either 2 days before the first Alternaria extract challenge or 1 day after the first Alternaria extract challenge.

Results

GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge decreased IL-33 release in the bronchoalveolar lavage fluid and dual oxidase 1 (Duox1) mRNA expression 1 hour after the first Alternaria extract challenge and IL-33 expression in lung epithelial cells 24 hours after the last Alternaria extract challenge. Furthermore, GLP-1R agonist significantly decreased the number of ILC2s expressing IL-5 and IL-13, lung protein expression of type 2 cytokines and chemokines, the number of perivascular eosinophils, mucus production, and airway responsiveness compared with vehicle treatment. GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge also significantly decreased eosinophilia and type 2 cytokine and chemokine expression in the airway after 4 days of Alternaria extract challenge.

Conclusion

These results reveal that GLP-1R signaling might be a therapy to reduce IL-33 release and inhibit the ILC2 response to protease-containing aeroallergens, such as Alternaria.

SUBMITTER: Toki S 

PROVIDER: S-EPMC9639650 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo.

Toki Shinji S   Goleniewska Kasia K   Reiss Sara S   Zhang Jian J   Bloodworth Melissa H MH   Stier Matthew T MT   Zhou Weisong W   Newcomb Dawn C DC   Ware Lorraine B LB   Stanwood Gregg D GD   Galli Aurelio A   Boyd Kelli L KL   Niswender Kevin D KD   Peebles R Stokes RS  

The Journal of allergy and clinical immunology 20180110 5


<h4>Background</h4>IL-33 is one of the most consistently associated gene candidates for asthma identified by using a genome-wide association study. Studies in mice and in human cells have confirmed the importance of IL-33 in inducing type 2 cytokine production from both group 2 innate lymphoid cells (ILC2s) and T<sub>H</sub>2 cells. However, there are no pharmacologic agents known to inhibit IL-33 release from airway cells.<h4>Objective</h4>We sought to determine the effect of glucagon-like pept  ...[more]

Similar Datasets

| S-EPMC8675188 | biostudies-literature
| S-EPMC7644167 | biostudies-literature
| S-EPMC7044202 | biostudies-literature
| S-EPMC7806479 | biostudies-literature
| S-EPMC6586630 | biostudies-literature
| S-EPMC5748848 | biostudies-literature
| S-EPMC5531601 | biostudies-literature
| S-EPMC7453888 | biostudies-literature
| S-EPMC5736420 | biostudies-literature
| S-EPMC6092330 | biostudies-literature